本人本年的工作情况如下： 杭州泰格医药科技股份有限公司 2024 年度独立董事述职报告 本人作为杭州泰格医药科技股份有限公司（以下简称"公司"）的独立董事，在 任职期间严格按照《中华人民共和国公司法》、《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》、《上市公司治理准则》、《上市公 司独立董事管理办法》、《公司章程》、《独立董事工作制度》等相关法律、法规、 规章制度及规范性文件的规定和要求，本着维护公司和股东尤其是中小股东的利益 的原则，积极参与公司的各项事务，客观、公正、独立地履行职责。 本人积极了解公司生产经营、发展战略和行业市场发展等情况，听取公司有关 人员的汇报，与公司经营管理层就公司决策、计划、执行结果等情况进行沟通、交 流，及时获悉公司各重大事项进展；关注外部环境及市场变化对公司的影响，维护 公司和中小股东的合法利益。本人勤勉尽责，保持客观独立性，在健全公司法人治 理结构、保证公司规范经营、规范关联交易等方面发挥应有的作用。本人对须经董 事会审议决策的重大事项，对涉及公司生产经营、人员选任、财务管理、关联交易 等重要事项，均进行了认真的核查，积极有效地履行了自己的职责。 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company's revenue decreased by 10.6% to RMB 6,603.1 million compared to RMB 7,384.0 million in 2023[2]. - Gross profit fell by 21.3% to RMB 2,242.0 million, down from RMB 2,848.5 million in the previous year[2]. - Net profit attributable to the company's owners dropped by 80.0% to RMB 405.1 million, compared to RMB 2,024.8 million in 2023[2]. - The company's cash and cash equivalents decreased significantly by 72.3% to RMB 2,048.5 million from RMB 7,399.9 million[3]. - The gross profit margin declined to 34.0% from 38.6%, representing a decrease of 4.6 percentage points[2]. - The company's total revenue decreased by 10.6% from RMB 7,384.0 million to RMB 6,603.1 million during the reporting period[37]. - Revenue from the clinical trial technology services segment fell by 23.8% from RMB 4,168.1 million to RMB 3,178.1 million[39]. - Revenue from clinical trial-related services and laboratory services increased by 6.5% from RMB 3,215.9 million to RMB 3,425.0 million[37]. - Revenue in China decreased by 16.2% from RMB 4,234.5 million to RMB 3,547.9 million, primarily due to a decline in clinical trial technology services[37]. - Overseas revenue slightly decreased by 3.0% from RMB 3,149.5 million to RMB 3,055.2 million, but showed growth when excluding specific vaccine-related income[38]. - The net profit for the period dropped by 79.2% from RMB 2,149.9 million to RMB 447.8 million, with profit attributable to shareholders decreasing by 80.0% from RMB 2,024.8 million to RMB 405.1 million[73]. - The non-IFRS net profit attributable to shareholders, excluding non-recurring items, was RMB 854.9 million, a decrease of 42.1% compared to RMB 1,477.2 million in the same period last year, with a profit margin decline from 20.0% to 12.9%[79]. Industry Trends and Developments - The domestic biopharmaceutical industry is expected to recover, with the clinical research outsourcing market projected to grow at an average annual rate of 12.6% from 2024 to 2028, reaching approximately RMB 75 billion by 2028[6]. - In 2024, the National Medical Products Administration approved 48 new Class I innovative drugs, an increase of 8 compared to 2023, marking a historical high[7]. - The number of clinical trials for innovative drugs reached 1,859, positioning China as the second globally in the number of new drugs under development[7]. - The biopharmaceutical industry is transitioning from "scale expansion" to "value creation," indicating a shift towards high-quality innovation[8]. - The Chinese government has increased support for innovative drug development, with policies covering research, review, application, payment, and financing across the entire chain of innovative drug development[10]. - By 2025, the Chinese government plans to implement a multi-payment mechanism for innovative drugs, enhancing support for pharmaceutical productivity development[11]. - The trend of outbound licensing transactions reflects the global market's high recognition of Chinese innovative drug companies' research and development products[12]. - The focus on innovative drug development has been highlighted in the 2024 government work report, emphasizing the importance of this emerging industry[10]. - The clinical trial review and approval reform aims to complete the review of innovative drug clinical trial applications within 30 working days[10]. - The application of AI technology is expected to enhance efficiency and cost optimization in clinical trials, leading to significant innovations in existing service models of clinical CROs[131]. Company Strategy and Operations - The company plans to distribute a final dividend of RMB 3.0 per 10 shares for the fiscal year ending December 31, 2024[3]. - The company achieved a net new contract amount of RMB 8.4 billion in 2024, representing a year-on-year growth of 7.3%, with a total contract amount to be executed reaching RMB 15.8 billion, up 12.0% year-on-year[15]. - The number of new customers increased by 22% year-on-year, driven by improved customer management strategies[14]. - The company established a Clinical Operations Strategy Committee to enhance clinical project success rates and facilitate order conversion[16]. - The company expanded its overseas clinical CRO business, with new contracts, revenue, and profits all experiencing rapid growth in 2024[17]. - The company maintained its leading position in the Chinese clinical outsourcing service market, with a market share ranking first according to data from the Ministry of Science and Technology[13]. - The company actively explored business opportunities from large multinational pharmaceutical companies and overseas clinical research, contributing to its growth in the domestic market[15]. - The company aims to enhance its end-to-end service capabilities through a unified clinical research service platform and expand its business with multinational and large domestic pharmaceutical companies[25]. - The company is focusing on digitalization and AI technology to improve efficiency and automation in clinical research and biopharmaceuticals[28]. - The company has established a Digital Advancement Center to drive its digital and intelligent strategy, with plans to implement AI across various business operations by early 2025[31]. Financial Position and Investments - The company's total assets as of December 31, 2024, amounted to RMB 28,671,015,787.16, a decrease from RMB 29,680,742,349.17 at the end of the previous year, reflecting a decline of approximately 3.4%[178][180]. - Current assets decreased significantly to RMB 6,299,685,225.86 from RMB 11,344,141,125.21, representing a drop of about 44.5% year-over-year[178]. - The company's cash and cash equivalents fell to RMB 2,055,344,830.04, down from RMB 7,419,991,842.25, indicating a decrease of approximately 72.3%[178]. - Total liabilities decreased to RMB 4,606,536,600.57 from RMB 5,227,180,203.91, a reduction of about 11.9%[180]. - The company's equity attributable to shareholders decreased to RMB 20,670,653,449.72 from RMB 21,026,774,725.75, reflecting a decline of approximately 1.7%[180]. - Long-term equity investments increased to RMB 3,424.6 million, mainly due to an investment of RMB 500.0 million in Hangzhou Taikun Equity Investment Fund[96]. - The total outstanding borrowings as of December 31, 2024, were RMB 2,315.8 million, with a short-term borrowing portion of RMB 1,992.2 million and a long-term borrowing portion of RMB 323.6 million[103]. - The company plans to utilize proceeds from fundraising to expand and enhance clinical trial technical services, repay bank loans, and for general corporate purposes[127]. - The company has accumulated experience in over 4,000 clinical trial projects, including more than 910 Phase I clinical trials for Class 1 drugs in China and over 140 international multi-regional clinical trials[116]. Employee and Governance - The global employee count reached 10,185, with over 1,600 overseas employees, reflecting growth due to the acquisition of Shanghai Guanhua Medical Technology Co., Ltd.[24]. - The company has established a labor union in China to represent employees in the formulation of company policies and internal regulations[153]. - The company has adopted the corporate governance code and has complied with its principles and provisions during the reporting period[154]. - The company has implemented a competitive salary and benefits package to attract, motivate, and retain employees[153]. - The company has conducted regular reviews of its workforce to ensure optimal talent composition to meet service demands[153]. - The company recognizes the importance of high-quality and stable employees for delivering quality services to clients and is committed to improving recruitment and training programs[152]. Risks and Challenges - The company faces risks related to obtaining and maintaining necessary regulatory approvals, licenses, and permits, which could significantly disrupt operations if not secured[144]. - There is a risk of losing customers if their expectations are not met, potentially leading to a reduction in revenue and inability to attract new clients[145]. - The loss of major clients or contracts could have a substantial negative impact on the company's business and financial performance[146]. - The company is facing increased payment risks from some clients due to financial difficulties, leading to order cancellations[40]. - The global pharmaceutical contract research organization market is becoming increasingly competitive, and failure to effectively compete could lead to reduced revenue and profitability[141]. - The company plans to continue selective acquisitions and investments to drive growth, but failure to identify suitable targets could adversely affect financial results[147].

一、2024年度日常关联交易基本情况 （一）日常关联交易概述 证券代码：300347 证券简称：泰格医药 公告编码（2025）013 号 杭州泰格医药科技股份有限公司 关于 2024 年度日常关联交易确认的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 经立信会计师事务所（特殊普通合伙）审计确认，2024年度杭州泰格医药科技股份有 限公司（以下简称"泰格医药"或"公司"）与关联人发生的日常关联交易金额为7,627.55万元。 2025年3月27日，公司第五届董事会第十四次会议以3票同意、0票反对、0票弃权，4票 回避，审议通过了《关于2024年度日常关联交易确认的议案》，关联董事叶小平先生、曹 晓春女士、吴灏先生、闻增玉先生回避表决。本次日常关联交易事项在董事会审批权限范 围内，无需提交2024年度股东会审议。 （二）2024年度日常关联交易实际发生情况 单位：万元 | 关联交易 类别 | 关联人 | 关联交易内容 | 实际发生金额 | 实际发生 额占同类 业务比例 | 披露日期 | | --- | --- | --- | --- | --- ...

公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 一、担保情况概述 公司控股孙公司方达制药（苏州）有限公司（以下简称"方达苏州"）因业务发展需要， 拟向境内中信银行股份有限公司苏州分行申请办理总金额不超过人民币1,000万元的授信 业务，用以补充公司经营资金。公司控股子公司方达医药技术（上海）有限公司（以下简 称"方达上海"）拟为上述授信业务提供连带责任保证，本次担保金额不超过人民币1,000万 元。 本次控股子公司方达上海为控股孙公司方达苏州提供担保是为满足其日常业务进一 步的发展需要，担保对象为公司合并报表范围内的控股子公司，风险可控，符合公司利益， 不会对公司的正常运作和业务发展产生不利影响。上述担保事项已经方达上海股东会作出 同意的决定，根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等相关规定，本次担保事项无需提交上 市公司董事会或股东大会审议批准。 二、被担保人基本情况 证券代码：300347 证券简称：泰格医药 公告编码（2025）019 号 杭州泰格医药科技股份有限公司 ...

杭州泰格医药科技股份有限公司 董事会审计委员会对会计师事务所履行监督职责情况报告 根据《中华人民共和国公司法》《上市公司治理准则》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定，杭州泰格医 药科技股份有限公司（以下简称"公司"）董事会审计委员会现将对立信会计师事务 所（特殊普通合伙）（以下简称"立信"）履行监督职责的情况汇报如下： 一、2024 年年审会计师事务所基本情况 1、会计师事务所基本情况 公司第五届董事会审计委员会2024年第一次会议、第五届董事会第六次会议及 2023年度股东会审议通过了《关于聘请公司2024年度审计机构的议案》，同意续聘 立信为公司2024年度审计机构。 二、审计委员会对会计师事务所监督情况 1 根据公司《董事会审计委员会工作细则》等有关规定，审计委员会对立信所履 行监督职责的情况如下： 1、公司于2024年3月27日召开第五届董事会审计委员会2024年第一次会议，审 议通过了《关于聘请公司2024年度审计机构的议案》。经查阅立信的基本情况，董 事会审计委员会认为其具备为公司提供审计工作的资质和专业能力，同意将该议案 提交公司第五届董事会第 ...

1 杭州泰格医药科技股份有限公司 关于独立董事独立性情况的专项意见 杭州泰格医药科技股份有限公司（以下简称"公司"）董事会根据《上市公司 独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等要求，并结合在任独立董事出具的《独立董事独立性自查报告》， 认为公司在任独立董事不存在任何妨碍其进行独立客观判断的关系，不存在影响独 立董事独立性的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规及《公司章程》 中关于独立董事的任职资格及独立性的要求。 杭州泰格医药科技股份有限公司董事会 二〇二五年三月二十八日 ...

杭州泰格医药科技股份有限公司董事会 二〇二五年三月二十八日 1 杭州泰格医药科技股份有限公司 关于独立董事独立性情况的专项意见 杭州泰格医药科技股份有限公司（以下简称"公司"）董事会根据《上市公司 独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等要求，并结合在任独立董事出具的《独立董事独立性自查报告》， 认为公司在任独立董事不存在任何妨碍其进行独立客观判断的关系，不存在影响独 立董事独立性的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规及《公司章程》 中关于独立董事的任职资格及独立性的要求。 ...

2025年3月27日，杭州泰格医药科技股份有限公司（以下简称"公司"）召开第五届董事 会第十四次会议和第五届监事会第九次会议，审议通过《关于向银行申请综合授信额度的 议案》，现将有关事项公告如下： 证券代码：300347 证券简称：泰格医药 公告编码（2025）018 号 杭州泰格医药科技股份有限公司 关于向银行申请综合授信额度的公告 公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误导性陈述或者 重大遗漏负连带责任。 一、为补充公司2025年度的流动资金需要，公司及纳入合并范围的子公司2025年度拟 向银行申请金额不超过人民币100亿元的综合授信额度（最终以各银行实际审批的授信额 度为准）。授信额度不等于公司的实际融资金额，实际融资金额应在授信额度内以公司及 纳入公司合并范围的子公司与银行实际发生的融资金额为准。 杭州泰格医药科技股份有限公司董事会 二〇二五年三月二十八日 二、前述授信包括但不限于：信贷借款、开立票据、信用证、保函及融资租赁。具体 授信额度、期限、利率及担保方式等条件以相关机构最终审批为准。 三、公司提请股东会授权法定代表人在上述授信额度范围内，决定申请授信的具体条 件 ...

证券代码：300347 在当今时代，全球正面临前所未有的变革与挑战，人类社会的可持续发展已成为全人类的 共同使命。作为医药行业的领军者，泰格医药深感责任重大。2024 年，我们迎来了公司 成立 20 周年的重要时刻，这不仅是泰格医药的里程碑，更是我们迈向全球医疗健康可持 续发展新征程的起点。 2024 泰格医药 可持续发展报告 目 录 CONTENTS | | 领导致辞 泰格医药档案 | 01 02 | | | | | | 04 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 05 | 可持续发展管理 | 06 | | 02 | | | | 育才与共，和衷共济 | 58 | | | | 80 | | | | 合规前进，行稳致远 | 21 | | | 人才成长与发展 | 60 | 生态共融，和谐共生 | | | 应对气候变化 | 01 | | 合规经营 商业道德 | | 24 28 | 03 | | 员工权益与福利 多元、平等与包容 | 69 73 | | 82 | | 环境保护 | | | ...

| 序号 | 原条款 | 修订后条款 | | --- | --- | --- | | | | 第十三条 公司的经营宗旨：结合各方在技术 | | | | 管理、运营以及营销方面的优势，在公司经批准 | | | 第十三条 公司的经营宗旨：结合各方在 | 的经营范围内开展业务，以取得良好的经济效 | | | 技术管理、运营以及营销方面的优势，在 | 益以及令各方满意的投资回报。 | | | 公司经批准的经营范围内开展业务，以取 | 经依法登记，公司的经营范围：一般项目：技术 | | | 得良好的经济效益以及令各方满意的投 | 服务、技术开发、技术咨询、技术交流、技术转 | | | 资回报。 | 让、技术推广；医学研究和试验发展（除人体干 | | | 经依法登记，公司的经营范围：服务：医 | 细胞、基因诊断与治疗技术开发和应用）；数据 | | | 药相关产业产品及健康相关产业产品的 | 处理和存储支持服务；数据处理服务；翻译服 | | | 技术开发、技术咨询、成果转让，临床试 | 务；业务培训（不含教育培训、职业技能培训等 | | 1 | 验数据的管理与统计分析，翻译，以承接 | 需取得许可的培训）；人力资源服务（不 ...